Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 888

1.

Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.

Mun SH, Won HY, Hernandez P, Aguila HL, Lee SK.

J Bone Miner Res. 2013 Apr;28(4):948-59. doi: 10.1002/jbmr.1787.

2.

Macrophage migration inhibitory factor inhibits osteoclastogenesis.

Jacquin C, Koczon-Jaremko B, Aguila HL, Leng L, Bucala R, Kuchel GA, Lee SK.

Bone. 2009 Oct;45(4):640-9. doi: 10.1016/j.bone.2009.06.028. Epub 2009 Jul 7.

PMID:
19591967
4.

Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.

Lee SK, Kalinowski JF, Jastrzebski SL, Puddington L, Lorenzo JA.

Endocrinology. 2003 Aug;144(8):3524-31.

PMID:
12865334
5.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
6.

Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.

Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, Yu J, Rho J, Kang JS.

Mar Drugs. 2014 Nov 24;12(11):5643-56. doi: 10.3390/md12115643.

7.

Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.

Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JM, Morand EF.

Cytokine. 2015 Apr;72(2):135-45. doi: 10.1016/j.cyto.2014.11.015. Epub 2015 Jan 31.

8.

Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.

Gong W, Dou H, Liu X, Sun L, Hou Y.

Clin Exp Pharmacol Physiol. 2012 Oct;39(10):886-93. doi: 10.1111/j.1440-1681.2012.12006.x.

PMID:
23013134
9.

NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.

Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF.

J Bone Miner Res. 2002 Jul;17(7):1200-10.

10.

The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.

Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.

Eur J Immunol. 2008 Jun;38(6):1598-609. doi: 10.1002/eji.200737650.

11.

IL-1 plays an important role in the bone metabolism under physiological conditions.

Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y.

Int Immunol. 2010 Oct;22(10):805-16. doi: 10.1093/intimm/dxq431. Epub 2010 Aug 2.

PMID:
20679512
12.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
14.

Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.

Ang ES, Pavlos NJ, Chai LY, Qi M, Cheng TS, Steer JH, Joyce DA, Zheng MH, Xu J.

J Cell Physiol. 2009 Dec;221(3):642-9. doi: 10.1002/jcp.21898.

PMID:
19681045
15.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

16.

Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.

Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.

Immunol Lett. 2014 Sep;161(1):31-7. doi: 10.1016/j.imlet.2014.04.006. Epub 2014 May 2.

PMID:
24792671
17.

Role of IGF-I signaling in regulating osteoclastogenesis.

Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD.

J Bone Miner Res. 2006 Sep;21(9):1350-8.

18.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

19.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
20.

Supplemental Content

Support Center